8-K current report · filed Jul 29, 2026

Axogen, Inc. (AXGN) 8-K Current Report: July 29, 2026

Item EX-99.1Item EX-99.2Item EX-99.3Item 7.01Item 2.02AXGN overview

Short answer

Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Axogen announced second-quarter 2026 financial results on July 29, 2026.

Axogen, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Axogen announced second-quarter 2026 financial results on July 29, 2026
  • Detailed revenue, earnings, guidance and operating metrics are in Exhibit 99.1
  • Results provide the latest quarterly update for investors assessing Axogen’s financial performance

Item 7.01 · Regulation FD Disclosure

  • Second-quarter 2026 financial results presentation released July 29, 2026
  • Updated corporate presentation released July 29, 2026
  • Investor materials available through Axogen’s investor-relations website and analyst discussions

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $69.7M, up 23.1% YoY; growth exceeded 50% in Breast, but product mix reduced gross margin to 72.7% from 74.2%
  • GAAP net loss $1.5M versus $0.6M income; adjusted net income $7.3M, while adjusted EBITDA fell to $8.4M from $9.3M
  • Full-year revenue guidance raised to at least $279M, representing at least 24% growth; gross margin target remains at least 73%
  • Balance sheet strengthened with $113.4M in cash, restricted cash, and investments; debt was eliminated following $48.6M repayment
  • Six-month free cash flow turned positive at $4.1M versus negative $7.2M; clinical studies and Trace Biosciences investment support longer-term adoption potential

Item EX-99.2 · Exhibit EX-99.2

  • Q2 revenue $69.7M, up 23.1% YoY, supporting full-year 2026 growth guidance of at least 24%, or $279M
  • Gross margin 74.2%, up 3.3 percentage points YoY, exceeding full-year guidance of at least 73%
  • Adjusted EBITDA $8.4M, margin 12.1% versus 16.3% YoY, showing growth investment is pressuring profitability
  • GAAP net loss $(1.5)M versus $0.6M income, while adjusted net income reached $7.3M and adjusted diluted EPS $0.12
  • Cash, equivalents, restricted cash and investments $113.4M, with no debt obligations and positive six-month free cash flow of $4.1M

Item EX-99.3 · Exhibit EX-99.3

  • Corporate presentation outlines Axogen’s 2025-2028 strategy, targeting 15%-20% prostate-market CAGR and broader commercial expansion
  • $5.6B US nerve-care opportunity across extremities, breast, oral/maxillofacial, head-and-neck, and prostate applications
  • 2026 guidance: revenue growth of at least 24% to $279M, gross margin of at least 73%, and positive free cash flow
  • CMS reimbursement tailwind: 2026 facility payment for CPT 64912 reaches $8,965 hospital outpatient and $6,157 ASC reimbursement
  • Coverage expansion: 61.8M additional lives added since Q2 2025 across Cigna, Elevance, and 10 regional Blue Cross Blue Shield plans

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Axogen, Inc. 8-K filings

Get the next AXGN 8-K as it lands

Follow AXGN for push alerts, or ask the research agent what this filing means.